Clinical Trial Search

Primary: HIV Infection in Infants Determined to be HIV Uninfected at 6 Weeks Enrolled in Each Arm of the Study — 8; 18; 700; 699 participants — p=0.049

Primary: Dried Blood Spot Analysis of Medication Adherence- Mother and Infant — 56; 157; 35; 183 Participants

Primary: Antepartum Component: Number of Confirmed Infant HIV Infections — 25; 7; 2 Participants

Primary: Number of Subjects With Any Cytomegalovirus (CMV) Congenital Infection — 24; 20; 4; 58 Participants

Primary: Number of Participants With Virologic Suppression — 274; 256; 160 Participants

Primary: HBsAG Prevalence — 22 Participants

Primary: Number of Participants With Lab Testing Acceptability Survey Scores >80% — 7; 41; 7; 40 Participants

Primary: Percentage of Infants With Hepatitis B Infection at 6 Months of Age — 0; 3 Participants

Primary: Peak Plasma Concentration of Etravirine in Plasma — 497.6 ng/ml

Primary: Rate of Maternal HIV Viral Suppression — 128; 132 Participants

Primary: Infant HIV Infection Status — 24; 11; 12 participants — p=.046

Primary: Proportion of Women With Plasma HIV-1 RNA Viral Load Less Than 200 Copies/mL at Delivery — .84; .94 Proportion — p=0.001

Primary: Percentage of Participants With Early Virologic Response — 80.8 percentage of participants

Primary: Incidence Rates of AIDS - Defining Illness, Serious Non-AIDS Defining, Cardiovascular, Renal, Hepatic Event, or Death — 0.21; 0.31 New cases per 100 person - years…

Primary: Percentage of Participants Failing to Meet Safety Endpoint Related to Maraviroc for Dose-Finding — 0; 0; 0; 0 percentage of participants

Primary: Outcome 1: Serial HIV-1 RNA Levels in Breastmilk. — 2.74; 2.03; 1.70; 1.70 Log10 Viral load copies/ml

Primary: Mean Change in HIV-1 Levels in Plasma Between 34 and 38 Weeks Gestation — -0.53; 0.03 log10 copies/mL

Primary: Number of Participants With Placental Malaria — 3; 6 Participants — p=0.50

Primary: Maternal HIV Incidence — 0.38; 0.31 incidence/100 Person years

Primary: Rate of Perinatal Transmission of SARS-CoV-2 — 12.3 percentage of participants

Primary: Feasibility of the Intervention - Number of Counseling Sessions — 2.92; 1 sessions

Primary: Time From Randomization to Virologic Failure or Death for Participants Who Had SD NVP Exposure Prior to Study Entry — 12; 60; 12; 84 weeks — p=<0.001

Primary: Incidence Rate of Combined Endpoint: Grade 3 or Higher Adverse Events (AEs) Related to Treatment, or AE Causing Discontinuation of Treatment — 15.03; 14.93 events per…

Primary: Number of Participants With the Composite Primary Outcome — 46; 37 Participants — p=0.42

Primary: Wechsler Preschool and Primary Scale of Intelligence, Third Edition (WPPSI-III) — 86.5; 87.4 Scores on a scale — p=0.59

Primary: Proportion of Time on Medication Among Pregnant Women — 0.67; 0.66 proportion of days with medicaiton

Primary: Number of Participants With New Circulating Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI)-Resistant Variants as Detected by Standard Composite (Bulk) Genotyping…

Primary: Maternal Mental Health — 8.5; 6.5; 3.0; 3.0 score on a scale

Primary: Plasmodium Falciparum Peripheral Parasitemia — 8; 7 Participants

Primary: Percent of Participants With Treatment Failure, Defined as a Confirmed Virologic Failure or Permanent Discontinuation of the Randomized NNRTI or PI Component of Study…